
USD
+$0.00
(+0.00%
)At Close (As of Dec 3, 2025)
$397.94M
Market Cap
19.77
P/E Ratio
0.35
EPS
$8.90
52 Week High
$5.52
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $70M |
| Total Revenue | $161M |
| Cost Of Revenue | $91M |
| Costof Goods And Services Sold | $91M |
| Operating Income | $20M |
| Selling General And Administrative | $20M |
| Research And Development | $15M |
| Operating Expenses | $50M |
| Investment Income Net | - |
| Net Interest Income | $1.5M |
| Interest Income | $2.1M |
| Interest Expense | $660K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $14M |
| Income Before Tax | $13M |
| Income Tax Expense | -$1.1M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $14M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $14M |
| Ebitda | $28M |
| Net Income | $14M |
| Field | Value (USD) |
|---|---|
| Total Assets | $372M |
| Total Current Assets | $184M |
| Cash And Cash Equivalents At Carrying Value | $78M |
| Cash And Short Term Investments | $78M |
| Inventory | $79M |
| Current Net Receivables | $23M |
| Total Non Current Assets | $188M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $102M |
| Intangible Assets Excluding Goodwill | $102M |
| Goodwill | $30M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $3.9M |
| Other Non Current Assets | - |
| Total Liabilities | $113M |
| Total Current Liabilities | $49M |
| Current Accounts Payable | $28M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $1.6M |
| Total Non Current Liabilities | $63M |
| Capital Lease Obligations | $11M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $11M |
| Other Current Liabilities | $20M |
| Other Non Current Liabilities | $53M |
| Total Shareholder Equity | $259M |
| Treasury Stock | - |
| Retained Earnings | -$26M |
| Common Stock | $15M |
| Common Stock Shares Outstanding | $58M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $48M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $14M |
| Capital Expenditures | $11M |
| Change In Receivables | - |
| Change In Inventory | $9.7M |
| Profit Loss | - |
| Cashflow From Investment | -$11M |
| Cashflow From Financing | -$14M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $14M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $70M |
| Total Revenue | $161M |
| Cost Of Revenue | $91M |
| Costof Goods And Services Sold | $91M |
| Operating Income | $20M |
| Selling General And Administrative | $20M |
| Research And Development | $15M |
| Operating Expenses | $50M |
| Investment Income Net | - |
| Net Interest Income | $1.5M |
| Interest Income | $2.1M |
| Interest Expense | $660K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $14M |
| Income Before Tax | $13M |
| Income Tax Expense | -$1.1M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $14M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $14M |
| Ebitda | $28M |
| Net Income | $14M |
| Field | Value |
|---|---|
| Ex Dividend Date | 2025-03-17 |
| Declaration Date | 2025-03-11 |
| Record Date | 2025-03-17 |
| Payment Date | 2025-04-07 |
| Amount | 0.2 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Kamada Ltd. is a biopharmaceutical company headquartered in Rehovot, Israel, focused on developing and commercializing plasma-derived protein therapies for rare diseases. With a diverse pipeline targeting critical unmet medical needs and leveraging proprietary technology, Kamada is committed to delivering innovative therapeutic solutions. The company's strategic emphasis on advancing patient care positions it as a compelling opportunity for institutional investors seeking exposure to a high-growth healthcare sector poised for continued evolution and expansion. As Kamada navigates the complexities of the biopharmaceutical landscape, it is well-prepared for sustained growth and impact in the market.